Sutilain

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Sutilain
Accession Number
DB09379
Type
Biotech
Groups
Approved, Withdrawn
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Sutilain is a member of the keratase family which includes agents such as papain. It is able to dissolve the intercellular matrix which helps with desquamation. Sutilain contains proteolytic enzymes derived from Bacillus subtilis and it is available as a cream-colored odorless powder. One gram of sutilain powder contains 250,000 casein units of proteolytic activity.2 Sutilain was developed by Abbott and FDA approved on June 12, 1969. It is currently discontinued.3

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Sutilaina
  • Sutilaines
  • Sutilains
External IDs
BAX 1515 / BAX-1515
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Travase Ointment 82000 Casein Units/gmOintment82000 unitTopicalBoots Pharmaceuticals Ltd.1987-12-311996-09-09Canada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
2PU6O23V1G
CAS number
12211-28-8

Pharmacology

Indication

Sutilain was indicated, in the form of an ointment, as a biochemical debridement of second and third-degree burns, incisional traumatic and pyrogenic wounds and ulcers occurring due to peripheral vascular diseases.2

Associated Therapies
Pharmacodynamics

Reports indicated that sutilain exhibited a rapid and effective debridement when used for the treatment of burns, decubiti and traumatic wounds. In the case of peripheral vascular ulcerations, it did not respond in a predictable manner.1 When used, sutilain caused a rapid dissolution of the surface of the treated skin zone. However, a graftable wound bed as achieved no more rapidly than if saline soaks had been used since the enzyme appears to be ineffective in removing deep dermal elements and necrotic fat.4

Mechanism of action

Sutilain is a proteolytic enzyme that dissolves necrotic tissue and hyaluronidase.[T170]

TargetActionsOrganism
ANecrotic TissueNot AvailableHumans
Absorption

Sutilain is not absorbed.

Volume of distribution

This pharmacokinetic parameter is not relevant.

Protein binding

This pharmacokinetic parameter is not relevant.

Metabolism

This pharmacokinetic parameter is not relevant.

Route of elimination

This pharmacokinetic parameter is not relevant.

Half life

This pharmacokinetic parameter is not relevant.

Clearance

This pharmacokinetic parameter is not relevant.

Toxicity

The toxicity has not been determined.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Coopwood TB: Evaluation of a topical enzymatic debridement agent--sutilains ointment: a preliminary report. South Med J. 1976 Jul;69(7):834-6. [PubMed:821152]
  2. Kokate C., Purohit A. and Gokhale S. (2008). Pharmacognosy (42nd ed.). Pragati Book House. [ISBN:978-81-96396-15-2]
  3. FDA approval [Link]
  4. US Army Annual progress report [Link]
External Links
PubChem Substance
347910450

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
OintmentTopical82000 unit
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

1. Necrotic Tissue
Kind
Action
Organism
Humans
Pharmacological action
Yes
References
  1. Coopwood TB: Evaluation of a topical enzymatic debridement agent--sutilains ointment: a preliminary report. South Med J. 1976 Jul;69(7):834-6. [PubMed:821152]

Drug created on November 30, 2015 12:10 / Updated on August 02, 2019 08:42